A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Inclusion Criteria:

• Provide a signed and dated informed consent form prior to initiation of study-specificprocedures.
• Patients with the indicated advanced or metastatic solid tumor as follows:

1. Microsatellite-stable colorectal cancer (MSS-CRC) who are currently receivingsystemic treatment with a fluoropyrimidine and oxaliplatin and/or irinotecan thatmay include a VEGF or EGFR targeting therapy as their 1L therapy for metastaticdisease OR who have experienced disease progression following treatment with afluoropyrimidine, oxaliplatin, and irinotecan that may include a VEGF or EGFRtargeting therapy and have not received additional lines of systemic therapy inthe metastatic setting.
2. Non-small cell lung cancer (NSCLC) who are currently receiving systemic treatmentwith an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-basedchemotherapy OR who have experienced disease progression following treatment withan anti-PD-(L)1 antibody in combination with cytotoxic, platinum-basedchemotherapy (or anti-PD-(L)1 alone if patient refuses platinum-basedchemotherapy), and have not received additional lines of systemic therapy in themetastatic setting.
3. Pancreatic ductal adenocarcinoma (PDA) who are currently receiving systemiccytotoxic chemotherapy as their 1L therapy for metastatic disease OR who haveexperienced disease progression on 1L systemic cytotoxic chemotherapy and havereceived no more than 1 prior line of therapy in the metastatic setting.
4. Any solid tumor histology where the patient has experienced disease progressionwith all available therapies known to confer clinical benefit

• Patient's tumor possesses one of the mutations listed below, and is determined toexpress a HLA allele for antigen presentation of the identified tumor mutation: VERSION 1.0 of the expression cassette: BRAF_G466V // CTNNB1_S37F // CTNNB1_S45F // CTNNB1_S45P // CTNNB1_T41A //ERBB2_Y772_A775dup // KRAS_G12C or NRAS_G12C // KRAS_G12D or NRAS_G12D // KRAS_G12V //KRAS_G13D // KRAS_Q61H or NRAS_Q61H // KRAS_Q61K or NRAS_Q61K // KRAS_Q61L or NRAS_Q61L //KRAS_Q61R or NRAS_Q61R // TP53_K132E // TP53_K132N // TP53_R213L // TP53_R249M //TP53_S127Y VERSION 2.0 of the expression cassette: KRAS_G12C or NRAS_G12C // KRAS_G12D or NRAS_G12D // KRAS_G12V or NRAS_G12V // KRAS_Q61H orNRAS_Q61H
• ECOG Performance Status 0 or 1
• Measurable disease according to RECIST v1.1
• Adequate organ function, as measured by laboratory values (criteria listed inprotocol)

Exclusion Criteria:

• Tumors with genetic characteristics as follows:

1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,RET, or TRK
2. Patients with known MSI-high disease based on institutional standard

• Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to avaccination
• Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significantbruising or bleeding following IM injections or blood draws
• History of allogenic/solid organ transplant
• Active, known, or suspected autoimmune disease
• Active tuberculosis or recent (<2 week) clinically significant infection, or evidenceof active hepatitis B or hepatitis C
• Known history of positive test for human immunodeficiency (HIV) or known acquiredimmunodeficiency syndrome (AIDS) Complete inclusion and exclusion criteria are listed in the clinical study protocol.